Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
暂无分享,去创建一个
J. Briones | A. López-Guillermo | L. Colomo | E. Montserrat | G. Gutiérrez-García | S. Mercadal | L. Escoda | I. Espinosa | R. Martino | J. Ribera | M. Camós | B. Xicoy | C. Pedro | C. Estany | I. Espinosa | S. Martínez | Josep-Maria Ribera
[1] W. Grody,et al. Mature T-Cell and NK-Cell Neoplasms , 2008 .
[2] W. Wilson,et al. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications , 2007, Current opinion in hematology.
[3] S. Ansell,et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Fanin,et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome , 2007, Leukemia.
[5] S. Smith,et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen , 2007, Bone Marrow Transplantation.
[6] Stefano A Pileri,et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. , 2007, The Journal of clinical investigation.
[7] C. Paolo,et al. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.
[8] T. Barbui,et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.
[9] S. Pileri,et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Gaulard,et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas , 2006, Oncogene.
[11] J. Vose. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. , 2005 .
[12] Terry L. Smith,et al. Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma , 2005, Cancer.
[13] A. Chott,et al. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab , 2005, Leukemia & lymphoma.
[14] Y. Kwong,et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] K. Savage. Aggressive peripheral T-cell lymphomas (specified and unspecified types). , 2005, Hematology. American Society of Hematology. Education Program.
[16] A. Stamatoullas,et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] R. Gascoyne,et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] S. Sacchi,et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T‐cell lymphomas, unspecified, and 496 diffuse large B‐cell lymphomas , 2004, Cancer.
[19] J. Benítez,et al. Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes , 2004, Clinical Cancer Research.
[20] M. Boccadoro,et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Erlanson,et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.
[22] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[23] F. d'Amore,et al. Stem Cell Transplantation for Peripheral T-Cell Lymphomas , 2004, Leukemia & lymphoma.
[24] K. Karube,et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. , 2004, Blood.
[25] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[26] A. F. Sevilla,et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[28] A. López-Guillermo,et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. , 2003, Haematologica.
[29] B. Nathwani,et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[31] B. Falini. Anaplastic large cell lymphoma: pathological, molecular and clinical features , 2001 .
[32] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. López-Guillermo,et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[35] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[36] S. Pileri,et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[38] F. Berger,et al. Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .
[39] D. Sainty,et al. [Peripheral T cell lymphoma]. , 1984, Nouvelle revue francaise d'hematologie.
[40] M. Pike,et al. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. , 1973, Biometrics.
[41] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[42] D.,et al. Regression Models and Life-Tables , 2022 .